{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:50:58Z","timestamp":1784260258029,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Low-density lipoprotein to high density lipoprotein (LDL\/HDL) cholesterol ratio has been reported to predict the risk of many metabolic diseases. However, the association between the LDL\/HDL cholesterol ratio and nonalcoholic fatty liver disease (NAFLD) has not been established.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A longitudinal cohort design was adopted in this study; 9767 non-obese subjects without NAFLD were included and analyzed. The subjects were grouped according to the quintile of LDL\/HDL cholesterol ratio. The cumulative incidence of NAFLD and the independent effect of the LDL\/HDL cholesterol ratio on NAFLD during 5\u2009years of follow-up were calculated using the Kaplan-Meier method and Cox proportional-hazards regression model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During the 5-year follow-up period, 841 subjects were diagnosed with new-onset NAFLD, and the 1-, 2-, 3-, 4-, and 5-year cumulative incidence rates of NAFLD were 1.16, 4.65, 8.33, 12.43, and 25.14%, respectively. In the multivariable-adjusted Cox proportional-hazards regression model, the LDL\/HDL cholesterol ratio was significantly associated with the risk for NAFLD (HR: 1.66, 95% CI: 1.38\u20131.99, <jats:italic>P<\/jats:italic> trend&lt;\u20090.001), especially among young people (HR: 3.96, 95% CI: 1.50\u201310.46, <jats:italic>P<\/jats:italic> interaction&lt;\u20090.05). Additionally, receiver operating characteristic curve analysis showed that the LDL\/HDL cholesterol ratio was better than HDL cholesterol and LDL cholesterol in predicting new-onset NAFLD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>LDL\/HDL cholesterol ratio is an independent predictor of NAFLD in Chinese non-obese people with normal lipids, and its predictive value is higher than that of other lipoproteins. In clinical practice, the LDL\/HDL cholesterol ratio can be used to identify people at high risk of NAFLD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12944-021-01457-1","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T12:03:08Z","timestamp":1616673788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["LDL\/HDL cholesterol ratio is associated with new-onset NAFLD in Chinese non-obese people with normal lipids: a 5-year longitudinal cohort study"],"prefix":"10.1186","volume":"20","author":[{"given":"Yang","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingchun","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5298-4724","authenticated-orcid":false,"given":"Guotai","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"1457_CR1","doi-asserted-by":"publisher","first-page":"ITC65","DOI":"10.7326\/AITC201811060","volume":"169","author":"XJ Wang","year":"2018","unstructured":"Wang XJ, Malhi H. Nonalcoholic fatty liver disease. Ann Intern Med. 2018;169:ITC65\u201380.","journal-title":"Ann Intern Med"},{"key":"1457_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cld.2017.08.007","volume":"22","author":"V Manne","year":"2018","unstructured":"Manne V, Handa P, Kowdley KV. Pathophysiology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. Clin Liver Dis. 2018;22:23\u201337.","journal-title":"Clin Liver Dis"},{"key":"1457_CR3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","volume":"70","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM. Non-alcoholic fatty liver disease - a global public health perspective. J Hepatol. 2019;70:531\u201344.","journal-title":"J Hepatol"},{"key":"1457_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1161\/CIRCRESAHA.119.316337","volume":"126","author":"J Cai","year":"2020","unstructured":"Cai J, Zhang XJ, Ji YX, Zhang P, She ZG, Li H. Nonalcoholic fatty liver disease pandemic fuels the upsurge in cardiovascular diseases. Circ Res. 2020;126:679\u2013704.","journal-title":"Circ Res"},{"key":"1457_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.gtc.2019.10.002","volume":"49","author":"J Wattacheril","year":"2020","unstructured":"Wattacheril J. Extrahepatic manifestations of nonalcoholic fatty liver disease. Gastroenterol Clin N Am. 2020;49:141\u20139.","journal-title":"Gastroenterol Clin N Am"},{"key":"1457_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology."},{"issue":"Suppl 1","key":"1457_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/liv.13643","volume":"38","author":"AR Ara\u00fajo","year":"2018","unstructured":"Ara\u00fajo AR, Rosso N, Bedogni G, Tiribelli C, Bellentani S. Global epidemiology of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis: what we need in the future. Liver Int. 2018;38(Suppl 1):47\u201351.","journal-title":"Liver Int"},{"key":"1457_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389\u201398.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1457_CR9","doi-asserted-by":"publisher","first-page":"8263","DOI":"10.3748\/wjg.v23.i47.8263","volume":"23","author":"BJ Perumpail","year":"2017","unstructured":"Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23:8263\u201376.","journal-title":"World J Gastroenterol"},{"key":"1457_CR10","doi-asserted-by":"publisher","first-page":"25168","DOI":"10.3390\/ijms161025168","volume":"16","author":"MC Hernandez-Rodas","year":"2015","unstructured":"Hernandez-Rodas MC, Valenzuela R, Videla LA. Relevant aspects of nutritional and dietary interventions in non-alcoholic fatty liver disease. Int J Mol Sci. 2015;16:25168\u201398.","journal-title":"Int J Mol Sci"},{"key":"1457_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","volume":"92","author":"SA Polyzos","year":"2019","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism. 2019;92:82\u201397.","journal-title":"Metabolism."},{"key":"1457_CR12","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.clnu.2018.08.008","volume":"38","author":"AY Wang","year":"2019","unstructured":"Wang AY, Dhaliwal J, Mouzaki M. Lean non-alcoholic fatty liver disease. Clin Nutr. 2019;38:975\u201381.","journal-title":"Clin Nutr"},{"key":"1457_CR13","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","volume":"5","author":"Q Ye","year":"2020","unstructured":"Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739\u201352.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1457_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12944-020-01326-3","volume":"19","author":"Y Zou","year":"2020","unstructured":"Zou Y, Yu M, Sheng G. Association between fasting plasma glucose and nonalcoholic fatty liver disease in a nonobese Chinese population with normal blood lipid levels: a prospective cohort study. Lipids Health Dis. 2020;19:145.","journal-title":"Lipids Health Dis"},{"key":"1457_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MD.0b013e3182779d49","volume":"91","author":"ZM Younossi","year":"2012","unstructured":"Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore). 2012;91:319\u201327.","journal-title":"Medicine (Baltimore)"},{"key":"1457_CR16","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/ajg.2012.314","volume":"107","author":"YM Kwon","year":"2012","unstructured":"Kwon YM, Oh SW, Hwang SS, Lee C, Kwon H, Chung GE. Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. Am J Gastroenterol. 2012;107:1852\u20138.","journal-title":"Am J Gastroenterol"},{"key":"1457_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.hbpd.2018.01.007","volume":"17","author":"SW Lee","year":"2018","unstructured":"Lee SW, Lee TY, Yang SS, Tung CF, Yeh HZ, Chang CS. Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: either non-obese or obese Chinese population. Hepatobiliary Pancreat Dis Int. 2018;17:45\u20138.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"1457_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/MED.0000000000000464","volume":"26","author":"AJ Amor","year":"2019","unstructured":"Amor AJ, Perea V. Dyslipidemia in nonalcoholic fatty liver disease. Curr Opin Endocrinol Diabetes Obes. 2019;26:103\u20138.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1457_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12944-020-01392-7","volume":"19","author":"XX Zhang","year":"2020","unstructured":"Zhang XX, Wei M, Shang LX, Lu YM, Zhang L, Li YD, et al. LDL-C\/HDL-C is associated with ischaemic stroke in patients with non-valvular atrial fibrillation: a case-control study. Lipids Health Dis. 2020;19:217.","journal-title":"Lipids Health Dis"},{"key":"1457_CR20","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3389\/fneur.2020.00408","volume":"11","author":"L Liu","year":"2020","unstructured":"Liu L, Yin P, Lu C, Li J, Zang Z, Liu Y, et al. Association of LDL-C\/HDL-C ratio with stroke outcomes within 1 year after onset: a hospital-based follow-up study. Front Neurol. 2020;11:408.","journal-title":"Front Neurol"},{"key":"1457_CR21","doi-asserted-by":"publisher","first-page":"600","DOI":"10.5551\/jat.37184","volume":"24","author":"SK Kunutsor","year":"2017","unstructured":"Kunutsor SK, Zaccardi F, Karppi J, Kurl S, Laukkanen JA. Is high serum LDL-C\/HDL-C cholesterol ratio an emerging risk factor for sudden cardiac death? Findings from the KIHD study. J Atheroscler Thromb. 2017;24:600\u20138.","journal-title":"J Atheroscler Thromb"},{"key":"1457_CR22","doi-asserted-by":"publisher","first-page":"e013781","DOI":"10.1136\/bmjopen-2016-013781","volume":"6","author":"DQ Sun","year":"2016","unstructured":"Sun DQ, Wu SJ, Liu WY, Wang LR, Chen YR, Zhang DC, et al. Association of low-density lipoprotein cholesterol within the normal range and NAFLD in the non-obese Chinese population: a cross-sectional and longitudinal study. BMJ Open. 2016;6:e013781.","journal-title":"BMJ Open"},{"key":"1457_CR23","doi-asserted-by":"publisher","unstructured":"Sun D-Q, et al. Data from: association of low-density lipoprotein cholesterol within the normal range and NAFLD in the non-obese Chinese population: a cross-sectional and longitudinal study, Dryad, dataset. 2016. https:\/\/doi.org\/10.5061\/dryad.1n6c4.","DOI":"10.5061\/dryad.1n6c4"},{"key":"1457_CR24","first-page":"20","volume-title":"Diagnosis and classification of diabetes mellitus and its complications\u2014part 1: diagnosis and classification of diabetes mellitus","author":"World Health Organization. Definition","year":"1999","unstructured":"World Health Organization. Definition. Diagnosis and classification of diabetes mellitus and its complications\u2014part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization; 1999. p. 20\u20131."},{"key":"1457_CR25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1751-2980.2008.00331.x","volume":"9","author":"MD Zeng","year":"2008","unstructured":"Zeng MD, Fan JG, Lu LG, Li YM, Chen CW, Wang BY, et al. Chinese National Consensus Workshop on nonalcoholic fatty liver disease. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. J Dig Dis. 2008;9:108\u201312.","journal-title":"J Dig Dis"},{"key":"1457_CR26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","volume":"30","author":"IR White","year":"2011","unstructured":"White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30:377\u201399.","journal-title":"Stat Med"},{"key":"1457_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/9780470316696","volume-title":"Multiple imputation for nonresponse in surveys","author":"DB Rubin","year":"1987","unstructured":"Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987."},{"key":"1457_CR28","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1016\/S1473-3099(16)30082-2","volume":"16","author":"EJA Fitchett","year":"2016","unstructured":"Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, et al. Strengthening the reporting of observational studies in epidemiology for newborn infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. Lancet Infect Dis. 2016;16:e202\u201313.","journal-title":"Lancet Infect Dis"},{"key":"1457_CR29","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.ijsu.2014.07.014","volume":"12","author":"JP Vandenbroucke","year":"2014","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, G\u00f8tzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Int J Surg. 2014;12:1500\u201324.","journal-title":"Int J Surg"},{"key":"1457_CR30","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/sim.4780080504","volume":"8","author":"S Durrleman","year":"1989","unstructured":"Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8:551\u201361.","journal-title":"Stat Med"},{"key":"1457_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12944-020-01213-x","volume":"19","author":"Z Chen","year":"2020","unstructured":"Chen Z, Hu H, Chen M, Luo X, Yao W, Liang Q, et al. Association of Triglyceride to high-density lipoprotein cholesterol ratio and incident of diabetes mellitus: a secondary retrospective analysis based on a Chinese cohort study. Lipids Health Dis. 2020;19:33.","journal-title":"Lipids Health Dis"},{"key":"1457_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jacc.2009.07.057","volume":"55","author":"BJ Arsenault","year":"2009","unstructured":"Arsenault BJ, Rana JS, Stroes ES, Despr\u00e9s JP, Shah PK, Kastelein JJ, et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol\/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol. 2009;55:35\u201341.","journal-title":"J Am Coll Cardiol"},{"key":"1457_CR33","doi-asserted-by":"publisher","first-page":"116","DOI":"10.14309\/ajg.0000000000000845","volume":"116","author":"JI Lee","year":"2021","unstructured":"Lee JI, Lee HW, Lee KS, Lee HS, Park JY. Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a Nationwide nested case-control study. Am J Gastroenterol. 2021;116:116\u201324.","journal-title":"Am J Gastroenterol"},{"key":"1457_CR34","first-page":"17","volume":"71","author":"VG Athyros","year":"2017","unstructured":"Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement Metabolism. 2017;71:17\u201332.","journal-title":"An Expert Panel Statement Metabolism"},{"key":"1457_CR35","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/liv.14116","volume":"39","author":"EH van den Berg","year":"2019","unstructured":"van den Berg EH, Wolters AAB, Dullaart RPF, Moshage H, Zurakowski D, de Meijer VE, et al. Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study. Liver Int. 2019;39:1343\u201354.","journal-title":"Liver Int"},{"key":"1457_CR36","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1002\/hep.29068","volume":"65","author":"I Doycheva","year":"2017","unstructured":"Doycheva I, Watt KD, Alkhouri N. Nonalcoholic fatty liver disease in adolescents and young adults: the next frontier in the epidemic. Hepatology. 2017;65:2100\u20139.","journal-title":"Hepatology."},{"key":"1457_CR37","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/1476-511X-9-138","volume":"9","author":"R Kawamoto","year":"2010","unstructured":"Kawamoto R, Tabara Y, Kohara K, Miki T, Kusunoki T, Takayama S, et al. Low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio is the best surrogate marker for insulin resistance in non-obese Japanese adults. Lipids Health Dis. 2010;9:138.","journal-title":"Lipids Health Dis"},{"key":"1457_CR38","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1111\/jgh.13335","volume":"31","author":"J Ampuero","year":"2016","unstructured":"Ampuero J, Ranchal I, Gallego-Dur\u00e1n R, Pareja MJ, Del Campo JA, Pastor-Ram\u00edrez H, et al. Oxidized low-density lipoprotein antibodies\/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients. J Gastroenterol Hepatol. 2016;31:1611\u20138.","journal-title":"J Gastroenterol Hepatol"},{"key":"1457_CR39","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/MOL.0b013e32832fa58d","volume":"20","author":"Y Ishigaki","year":"2009","unstructured":"Ishigaki Y, Oka Y, Katagiri H. Circulating oxidized LDL: a biomarker and a pathogenic factor. Curr Opin Lipidol. 2009;20:363\u20139.","journal-title":"Curr Opin Lipidol"},{"key":"1457_CR40","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3390\/biom10040534","volume":"10","author":"C Santiago-Fern\u00e1ndez","year":"2020","unstructured":"Santiago-Fern\u00e1ndez C, Martin-Reyes F, Tome M, Oca\u00f1a-Wilhelmi L, Rivas-Becerra J, Tatzber F, et al. Oxidized LDL modify the human adipocyte phenotype to an insulin resistant, Proinflamatory and Proapoptotic profile. Biomolecules. 2020;10:534.","journal-title":"Biomolecules."},{"key":"1457_CR41","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12944-017-0572-9","volume":"16","author":"Z Chen","year":"2017","unstructured":"Chen Z, Yu R, Xiong Y, Du F, Zhu S. A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. Lipids Health Dis. 2017;16:203.","journal-title":"Lipids Health Dis"},{"key":"1457_CR42","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3390\/nu12020499","volume":"12","author":"R Valenzuela","year":"2020","unstructured":"Valenzuela R, Videla LA. Impact of the co-administration of N-3 fatty acids and olive oil components in preclinical nonalcoholic fatty liver disease models: a mechanistic view. Nutrients. 2020;12:499.","journal-title":"Nutrients."},{"key":"1457_CR43","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1055\/s-0033-1358519","volume":"33","author":"DE Cohen","year":"2013","unstructured":"Cohen DE, Fisher EA. Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease. Semin Liver Dis. 2013;33:380\u20138.","journal-title":"Semin Liver Dis"},{"key":"1457_CR44","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KG Alberti","year":"2009","unstructured":"Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; world heart federation; international atherosclerosis society; and International Association for the Study of obesity. Circulation. 2009;120:1640\u20135.","journal-title":"Circulation."},{"key":"1457_CR45","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.cgh.2016.08.028","volume":"15","author":"D Kim","year":"2017","unstructured":"Kim D, Kim WR. Nonobese fatty liver disease. Clin Gastroenterol Hepatol. 2017;15:474\u201385.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01457-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12944-021-01457-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01457-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T12:04:03Z","timestamp":1616673843000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-021-01457-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1457"],"URL":"https:\/\/doi.org\/10.1186\/s12944-021-01457-1","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]},"assertion":[{"value":"18 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Because of the previous study has been approved by the institutional review boards of Wenzhou people\u2019s Hospital and the written informed consent of the participants, there was no need to apply for ethical approval again for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}